Clinical Trials Logo

Refractory Biphenotypic Leukemia clinical trials

View clinical trials related to Refractory Biphenotypic Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02091245 Active, not recruiting - Clinical trials for Refractory Acute Lymphoblastic Leukemia (ALL)

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Start date: March 2014
Phase: Phase 1
Study type: Interventional

This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.